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Antidrug Antibodies in Patients Treated with Alirocumab
To the Editor: Immunogenicity led to the dis­
continuation of clinical development of boco­
cizumab, a murine­derived, humanized antibody 
to proprotein convertase subtilisin–kexin type 9 
(PCSK9), as now described by Ridker et al.1 in 
the Journal. Evidence suggests increased immuno­
genicity potential for murine­derived antibodies 
humanized by artificially engineering them in 
vitro, as compared with fully human antibodies 
that are produced with the use of mice with 
genetically humanized immune systems.
Very low rates of immunogenicity were ob­
served in clinical trials of alirocumab, a fully hu­
man PCSK9 antibody derived from VelocImmune 
mice (in which the murine genes in the heavy­
chain and light­chain immunoglobulin variable 
region are replaced with their human counter­
parts).2­4 We evaluated the effect of antidrug 
antibodies on the safety and efficacy of alirocu­
mab with respect to reductions in levels of low­
density lipoprotein (LDL) cholesterol using data 
from 10 trials involving 4747 patients (Tables S1 
and S2 in the Supplementary Appendix, available 
with the full text of this letter at NEJM.org). 
Antidrug antibodies were assessed with the use 
of a validated assay with positivity set to maximize 
sensitivity, which resulted in false positives in a 
low percentage of baseline and control samples.
Antidrug antibodies were observed in 155 of 
3039 patients (5.1%) in the alirocumab group 
and in 17 of 1708 (1.0%) in the control group. 
Persistent antidrug antibodies (i.e., ≥2 consecu­
tive positive samples over ≥12 weeks) were found 
in 44 patients (1.4%) in the alirocumab group 
and in 3 (0.2%) in the control group (Table S3 in 
the Supplementary Appendix). To evaluate the 
potential effect of antidrug antibodies on effi­
cacy, we compared patients without antidrug 
antibodies with those who had persistent or 
transient antidrug antibodies using a mixed­
effect model with repeated measures (Fig. 1, and 
the Methods section in the Supplementary Ap­
pendix).
According to regulatory guidance,5 we rea­
soned that the presence of persistent antidrug 
antibodies would most likely influence efficacy. 
However, we found that substantial reductions 
in LDL cholesterol levels were maintained over 
the course of the studies, regardless of antidrug­
antibody status, although for some time points, 
nominally significant differences (not adjusted 
for multiple testing) were noted (Fig. 1, and Ta­
ble S4 in the Supplementary Appendix). In a trend 
analysis, no late loss in the LDL­cholesterol re­
sponse was seen in patients with antidrug anti­
bodies. Mean reductions in LDL cholesterol were 
also maintained over time in patients with neu­
tralizing antibodies (antidrug antibodies that 
inhibit binding), which were observed in 1.3% of 
the patients (Table S5 and Fig. S1 in the Supple­
mentary Appendix). Among the patients who 
received alirocumab, adverse events occurred at 
similar frequencies regardless of antidrug­anti­
body status, although injection­site reactions 
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(mostly mild) were more frequent among the 
patients with antidrug antibodies (Table S6 in 
the Supplementary Appendix).
In conclusion, antidrug antibodies developed 
in few patients who were treated with alirocumab, 
and even those patients had substantial and du­
rable evidence of LDL­cholesterol lowering. How­
ever, these findings are limited by the small 
number of patients in whom antidrug antibodies 
developed. Since immunogenicity data are depen­
dent on numerous factors, comparisons of anti­
drug­antibody incidence among different drugs 
(even in the same class) may be misleading.
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Figure 1. LDL Cholesterol Levels in Patients Who Received Alirocumab, 
 According to Antidrug-Antibody (ADA) Status.
Panel A shows data from ODYSSEY LONG TERM, which involved patients 
who received 150 mg of alirocumab every 2 weeks. Panel B shows the results 
of a meta-analysis of eight phase 3 ODYSSEY trials (FH I, FH II, COMBO I, 
COMBO II, OPTIONS I, OPTIONS II, MONO, and ALTERNATIVE) in which 
patients received 75 mg of alirocumab every 2 weeks with a possible dose 
increase to 150 mg every 2 weeks, depending on the low-density lipoprotein 
(LDL) cholesterol level at 8 weeks. (References for all the trials cited here 
are provided in the Supplementary Appendix.) Although immunogenicity 
data were compiled from 10 studies involving all 4747 patients, the 10th trial 
(ODYSSEY HIGH FH) was not included in the efficacy analyses, since it 
did not have any patients with persistent antidrug antibodies (i.e., those 
occurring in ≥2 consecutive samples over ≥12 weeks). Transient antidrug 
antibodies include those that were defined as either indeterminate (present 
only at the last sampling time point) or transient (any positive antidrug-anti-
body response that was considered to be neither persistent nor indetermi-
nate). Among the patients in whom no antidrug antibodies developed, the 
least-squares (LS) mean LDL cholesterol level at 78 weeks was 52.2 mg per 
deciliter in Panel A and 65.3 mg per deciliter in Panel B. Among the patients 
with transient antidrug antibodies, the values were 58.6 mg per deciliter 
and 56.2 mg per deciliter, respectively; among those with persistent anti-
drug antibodies, the values were 60.1 mg per deciliter and 65.7 mg per deci-
liter, respectively. The I bars denote 95% confidence intervals. To convert 
the values for cholesterol to millimoles per liter, multiply by 0.02586.
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